Melnick, Ari M.

Publications

Sort by

Co-Author Network

selected publications

Correction: Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. Blood cancer journal. 2023 Article GET IT
Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL. Blood. 2023 Academic Article GET IT
Times cited: 5
Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity. Haematologica. 2023 Academic Article GET IT
Combinatorial treatment rescues tumour-microenvironment-mediated attenuation of MALT1 inhibitors in B-cell lymphomas. Nature materials. 2023 Academic Article GET IT
Times cited: 4
Cooperative super-enhancer inactivation caused by heterozygous loss of CREBBP and KMT2D skews B cell fate decisions and yields T cell-depleted lymphomas. bioRxiv : the preprint server for biology. 2023 Article GET IT
Endothelial cell-leukemia interactions remodel drug responses, uncovering T-ALL vulnerabilities. Blood. 2023 Academic Article GET IT
Times cited: 1
IDH2 and TET2 mutations synergize to modulate T Follicular Helper cell functional interaction with the AITL microenvironment. Cancer cell. 2023 Academic Article GET IT
Times cited: 1
BTG1 mutation yields supercompetitive B cells primed for malignant transformation. Science (New York, N.Y.). 2023 Academic Article GET IT
Distinct and opposite effects of leukemogenic Idh and Tet2 mutations in hematopoietic stem and progenitor cells. Proceedings of the National Academy of Sciences of the United States of America. 2023 Academic Article GET IT
Times cited: 2
An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery. 2023 Editorial Article GET IT
Times cited: 3
Distinct Genetically Determined Origins of Myd88/BCL2-Driven Aggressive Lymphoma Rationalize Targeted Therapeutic Intervention Strategies. Blood cancer discovery. 2023 Editorial Article GET IT
Times cited: 1
Genomic profiling for clinical decision making in lymphoid neoplasms. Blood. 2022 Academic Article GET IT
Times cited: 21
TP53 mutations and RNA-binding protein MUSASHI-2 drive resistance to PRMT5-targeted therapy in B-cell lymphoma. Nature communications. 2022 Academic Article GET IT
Times cited: 2
Integrative analysis identifies an older female-linked AML patient group with better risk in ECOG-ACRIN Cancer Research Group's clinical trial E3999. Blood cancer journal. 2022 Letter GET IT
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee. Blood. 2022 Academic Article GET IT
Times cited: 192
Tee-ing up a New Follicular Lymphoma Classification System. Blood cancer discovery. 2022 Editorial Article GET IT
BCL10 Mutations Define Distinct Dependencies Guiding Precision Therapy for DLBCL. Cancer discovery. 2022 Academic Article GET IT
Times cited: 3
Taking the EZ way: Targeting enhancer of zeste homolog 2 in B-cell lymphomas. Blood reviews. 2022 Review GET IT
Times cited: 4
SETD2 Haploinsufficiency Enhances Germinal Center-Associated AICDA Somatic Hypermutation to Drive B-cell Lymphomagenesis. Cancer discovery. 2022 Academic Article GET IT
Times cited: 4
Diverging regulation of Bach2 protein and RNA expression determine cell fate in early B cell response. Cell reports. 2022 Academic Article GET IT
Times cited: 1
Identifying synergistic high-order 3D chromatin conformations from genome-scale nanopore concatemer sequencing. Nature biotechnology. 2022 Academic Article GET IT
Times cited: 10
Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma. The Journal of clinical investigation. 2022 Academic Article GET IT
Times cited: 10
3D chromosomal architecture in germinal center B cells and its alterations in lymphomagenesis. Current opinion in genetics & development. 2022 Review GET IT
Conformational transitions in BTG1 antiproliferative protein and their modulation by disease mutants. Biophysical journal. 2022 Academic Article GET IT
Times cited: 3
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. Science translational medicine. 2022 Academic Article GET IT
Times cited: 3
Histone 3 Methyltransferases Alter Melanoma Initiation and Progression Through Discrete Mechanisms. Frontiers in cell and developmental biology. 2022 Academic Article GET IT
Times cited: 62
Intravital three-photon microscopy allows visualization over the entire depth of mouse lymph nodes. Nature immunology. 2022 Academic Article GET IT
Times cited: 14
System-wide transcriptome damage and tissue identity loss in COVID-19 patients. Cell reports. Medicine. 2022 Academic Article GET IT
Times cited: 13
Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies. Frontiers in cell and developmental biology. 2022 Review GET IT
Times cited: 183
Landscape and clinical significance of long noncoding RNAs involved in multiple myeloma expressed fusion transcripts. American journal of hematology. 2022 Letter GET IT
Times cited: 1
Loss of function mutations of BCOR in classical Hodgkin lymphoma. Leukemia & lymphoma. 2021 Academic Article GET IT
Times cited: 1
Author Correction: The SEQC2 epigenomics quality control (EpiQC) study. Genome biology. 2021 Article GET IT
The SEQC2 epigenomics quality control (EpiQC) study. Genome biology. 2021 Academic Article GET IT
Times cited: 9
Targeting MALT1 for the treatment of diffuse large B-cell lymphoma. Leukemia & lymphoma. 2021 Review GET IT
Times cited: 7
Translational Activation of ATF4 through Mitochondrial Anaplerotic Metabolic Pathways Is Required for DLBCL Growth and Survival. Blood cancer discovery. 2021 Academic Article GET IT
Times cited: 5
Dissecting bulk transcriptomes of diffuse large B cell lymphoma. Cancer cell. 2021 Comment GET IT
Histone H1 Mutations in Lymphoma: A Link(er) between Chromatin Organization, Developmental Reprogramming, and Cancer. Cancer research. 2021 Review GET IT
Times cited: 5
OCT2 pre-positioning facilitates cell fate transition and chromatin architecture changes in humoral immunity. Nature immunology. 2021 Academic Article GET IT
Times cited: 4
Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes. Frontiers in immunology. 2021 Academic Article GET IT
Times cited: 2
Molecular classification improves risk assessment in adult BCR-ABL1-negative B-ALL. Blood. 2021 Academic Article GET IT
Times cited: 36
DNA methylation landscapes of 1538 breast cancers reveal a replication-linked clock, epigenomic instability and cis-regulation. Nature communications. 2021 Academic Article GET IT
Times cited: 13
KDM5 inhibition offers a novel therapeutic strategy for the treatment of KMT2D mutant lymphomas. Blood. 2021 Academic Article GET IT
Times cited: 23
Allele-specific expression of GATA2 due to epigenetic dysregulation in CEBPA double-mutant AML. Blood. 2021 Academic Article GET IT
Times cited: 4
Combined epigenetic and metabolic treatments overcome differentiation blockade in acute myeloid leukemia. iScience. 2021 Academic Article GET IT
Times cited: 2
Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma. Leukemia. 2021 Academic Article GET IT
Times cited: 4
Progress toward B-Cell Lymphoma 6 BTB Domain Inhibitors for the Treatment of Diffuse Large B-Cell Lymphoma and Beyond. Journal of medicinal chemistry. 2021 Academic Article GET IT
Times cited: 13
Non-oncogene Addiction to SIRT5 in Acute Myeloid Leukemia. Blood cancer discovery. 2021 Comment GET IT
Times cited: 1
Cyclin D3 drives inertial cell cycling in dark zone germinal center B cells. The Journal of experimental medicine. 2021 Academic Article GET IT
Times cited: 26
An Esrrb and Nanog Cell Fate Regulatory Module Controlled by Feed Forward Loop Interactions. Frontiers in cell and developmental biology. 2021 Academic Article GET IT
Times cited: 120
Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2 infection reveals unique host responses, viral diversification, and drug interactions. Nature communications. 2021 Academic Article GET IT
Times cited: 67
Systemic Tissue and Cellular Disruption from SARS-CoV-2 Infection revealed in COVID-19 Autopsies and Spatial Omics Tissue Maps. bioRxiv : the preprint server for biology. 2021 Article GET IT
Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma. Leukemia. 2021 Academic Article GET IT
Times cited: 20
Genomic and evolutionary portraits of disease relapse in acute myeloid leukemia. Leukemia. 2021 Academic Article GET IT
Times cited: 6
BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells. Blood. 2021 Academic Article GET IT
Times cited: 12
Identification of MALT1 feedback mechanisms enables rational design of potent antilymphoma regimens for ABC-DLBCL. Blood. 2021 Academic Article GET IT
Times cited: 17
Clonal hematopoiesis before, during, and after human spaceflight. Cell reports. 2021 Article GET IT
Times cited: 4
Clinical and Biological Subtypes of B-cell Lymphoma Revealed by Microenvironmental Signatures. Cancer discovery. 2021 Academic Article GET IT
Times cited: 68
Chemotherapy Induces Senescence-Like Resilient Cells Capable of Initiating AML Recurrence. Cancer discovery. 2021 Academic Article GET IT
Times cited: 73
Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation. Nature immunology. 2021 Academic Article GET IT
Times cited: 17
An Embryonic Diapause-like Adaptation with Suppressed Myc Activity Enables Tumor Treatment Persistence. Cancer cell. 2021 Academic Article GET IT
Times cited: 73
An Autochthonous Mouse Model of Myd88- and BCL2-Driven Diffuse Large B-cell Lymphoma Reveals Actionable Molecular Vulnerabilities. Blood cancer discovery. 2021 Academic Article GET IT
Times cited: 14
Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL). Current cancer drug targets. 2021 Review GET IT
Times cited: 9
H1 histones control the epigenetic landscape by local chromatin compaction. Nature. 2020 Academic Article GET IT
Times cited: 60
Histone H1 loss drives lymphoma by disrupting 3D chromatin architecture. Nature. 2020 Academic Article GET IT
Times cited: 95
Epigenetic Mechanisms in Leukemias and Lymphomas. Cold Spring Harbor perspectives in medicine. 2020 Review GET IT
Times cited: 10
Cell-free DNA (cfDNA) and Exosome Profiling from a Year-Long Human Spaceflight Reveals Circulating Biomarkers. iScience. 2020 Academic Article GET IT
Times cited: 19
Circulating miRNA Spaceflight Signature Reveals Targets for Countermeasure Development. Cell reports. 2020 Academic Article GET IT
Times cited: 23
Clonal Hematopoiesis Before, During, and After Human Spaceflight. Cell reports. 2020 Academic Article GET IT
Times cited: 15
Multi-omic, Single-Cell, and Biochemical Profiles of Astronauts Guide Pharmacological Strategies for Returning to Gravity. Cell reports. 2020 Academic Article GET IT
Times cited: 22
Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage. Molecular cell. 2020 Academic Article GET IT
Times cited: 15
The dangers of déjà vu: memory B cells as the cells of origin of ABC-DLBCLs. Blood. 2020 Academic Article GET IT
Times cited: 14
Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood advances. 2020 Academic Article GET IT
Times cited: 20
Targeted detection and quantitation of histone modifications from 1,000 cells. PloS one. 2020 Academic Article GET IT
Times cited: 1
Somatic Mutations Drive Specific, but Reversible, Epigenetic Heterogeneity States in AML. Cancer discovery. 2020 Academic Article GET IT
Times cited: 14
Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. Genome research. 2020 Academic Article GET IT
Times cited: 22
TBL1XR1 Mutations Drive Extranodal Lymphoma by Inducing a Pro-tumorigenic Memory Fate. Cell. 2020 Academic Article GET IT
Times cited: 40
The serine hydroxymethyltransferase-2 (SHMT2) initiates lymphoma development through epigenetic tumor suppressor silencing. Nature cancer. 2020 Academic Article GET IT
Times cited: 25
TET2 deficiency reprograms the germinal center B cell epigenome and silences genes linked to lymphomagenesis. Science advances. 2020 Academic Article GET IT
Times cited: 25
Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response. Cancer cell. 2020 Academic Article GET IT
Times cited: 70
Shotgun Transcriptome and Isothermal Profiling of SARS-CoV-2 Infection Reveals Unique Host Responses, Viral Diversification, and Drug Interactions. bioRxiv : the preprint server for biology. 2020 Article GET IT
The oncogene BCL6 is up-regulated in glioblastoma in response to DNA damage, and drives survival after therapy. PloS one. 2020 Academic Article GET IT
Times cited: 6
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer discovery. 2020 Academic Article GET IT
Times cited: 78
The therapeutic landscape for cells engineered with chimeric antigen receptors. Nature biotechnology. 2020 Academic Article GET IT
Times cited: 110
Dynamic Incorporation of Histone H3 Variants into Chromatin Is Essential for Acquisition of Aggressive Traits and Metastatic Colonization. Cancer cell. 2019 Academic Article GET IT
Times cited: 44
An "EZ" Epigenetic Road to Leukemia Stem Cell Metabolic Reprogramming?. Cancer discovery. 2019 Comment GET IT
Times cited: 2
Therapeutic Targeting of RNA Splicing Catalysis through Inhibition of Protein Arginine Methylation. Cancer cell. 2019 Academic Article GET IT
Times cited: 131
Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia. Genes & development. 2019 Academic Article GET IT
Times cited: 13
Emerging epigenetic-modulating therapies in lymphoma. Nature reviews. Clinical oncology. 2019 Review GET IT
Times cited: 71
MTA2/NuRD Regulates B Cell Development and Cooperates with OCA-B in Controlling the Pre-B to Immature B Cell Transition. Cell reports. 2019 Academic Article GET IT
Times cited: 16
Role of chromosomal architecture in germinal center B cells and lymphomagenesis. Current opinion in hematology. 2019 Review GET IT
Times cited: 6
Non-oncogene Addiction to SIRT3 Plays a Critical Role in Lymphomagenesis. Cancer cell. 2019 Academic Article GET IT
Times cited: 60
BCL6 modulates tissue neutrophil survival and exacerbates pulmonary inflammation following influenza virus infection. Proceedings of the National Academy of Sciences of the United States of America. 2019 Academic Article GET IT
Times cited: 41
Quinoline and thiazolopyridine allosteric inhibitors of MALT1. Bioorganic & medicinal chemistry letters. 2019 Academic Article GET IT
Times cited: 11
Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML. Cancer discovery. 2019 Academic Article GET IT
Times cited: 28
Corrupted coordination of epigenetic modifications leads to diverging chromatin states and transcriptional heterogeneity in CLL. Nature communications. 2019 Academic Article GET IT
Times cited: 46
The NASA Twins Study: A multidimensional analysis of a year-long human spaceflight. Science (New York, N.Y.). 2019 Academic Article GET IT
Times cited: 466
PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas. Blood. 2019 Academic Article GET IT
Times cited: 47
Peptide-based covalent inhibitors of MALT1 paracaspase. Bioorganic & medicinal chemistry letters. 2019 Academic Article GET IT
Times cited: 13
Germinal center-derived lymphomas: The darkest side of humoral immunity. Immunological reviews. 2019 Review GET IT
Times cited: 88
The Impact of Heterogeneity on Single-Cell Sequencing. Frontiers in genetics. 2019 Academic Article GET IT
Times cited: 1084
BCL6 Evolved to Enable Stress Tolerance in Vertebrates and Is Broadly Required by Cancer Cells to Adapt to Stress. Cancer discovery. 2019 Academic Article GET IT
Times cited: 26
Long non-coding RNAs discriminate the stages and gene regulatory states of human humoral immune response. Nature communications. 2019 Academic Article GET IT
Times cited: 62
Molecular and Genetic Characterization of MHC Deficiency Identifies EZH2 as Therapeutic Target for Enhancing Immune Recognition. Cancer discovery. 2019 Academic Article GET IT
Times cited: 161
Histone demethylase LSD1 is required for germinal center formation and BCL6-driven lymphomagenesis. Nature immunology. 2018 Academic Article GET IT
Times cited: 53
Untangling the Role of Polycomb Complexes in Chemotherapy Resistance. Cancer discovery. 2018 Comment GET IT
Times cited: 3
Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. Blood. 2018 Academic Article GET IT
Times cited: 16
TET2 Deficiency Causes Germinal Center Hyperplasia, Impairs Plasma Cell Differentiation, and Promotes B-cell Lymphomagenesis. Cancer discovery. 2018 Academic Article GET IT
Times cited: 101
PRMT5 interacts with the BCL6 oncoprotein and is required for germinal center formation and lymphoma cell survival. Blood. 2018 Academic Article GET IT
Times cited: 43
Genetic and epigenetic evolution as a contributor to WT1-mutant leukemogenesis. Blood. 2018 Academic Article GET IT
Times cited: 29
Specific covalent inhibition of MALT1 paracaspase suppresses B cell lymphoma growth. The Journal of clinical investigation. 2018 Academic Article GET IT
Times cited: 40
Identification of Thiourea-Based Inhibitors of the B-Cell Lymphoma 6 BTB Domain via NMR-Based Fragment Screening and Computer-Aided Drug Design. Journal of medicinal chemistry. 2018 Academic Article GET IT
Times cited: 28
Ex vivo synthetic immune tissues with T cell signals for differentiating antigen-specific, high affinity germinal center B cells. Biomaterials. 2018 Academic Article GET IT
Times cited: 23
How Biophysical Forces Regulate Human B Cell Lymphomas. Cell reports. 2018 Academic Article GET IT
Times cited: 20
ORY-1001, a Potent and Selective Covalent KDM1A Inhibitor, for the Treatment of Acute Leukemia. Cancer cell. 2018 Academic Article GET IT
Times cited: 175
MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia. Cancer discovery. 2018 Academic Article GET IT
Times cited: 47
Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs. Molecular cell. 2018 Academic Article GET IT
Times cited: 1
AICDA drives epigenetic heterogeneity and accelerates germinal center-derived lymphomagenesis. Nature communications. 2018 Academic Article GET IT
Times cited: 42
Cooperative Epigenetic Remodeling by TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity. Cancer cell. 2017 Academic Article GET IT
Times cited: 61
Central role of myeloid MCPIP1 in protecting against LPS-induced inflammation and lung injury. Signal transduction and targeted therapy. 2017 Academic Article GET IT
Times cited: 41
EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop. Nature communications. 2017 Academic Article GET IT
Times cited: 109
MALT1 Inhibition Is Efficacious in Both Naïve and Ibrutinib-Resistant Chronic Lymphocytic Leukemia. Cancer research. 2017 Academic Article GET IT
Times cited: 35
Untangling the Web of Lymphoma Somatic Mutations. Cell. 2017 Comment GET IT
Times cited: 1
The N⁶-methyladenosine (m⁶A)-forming enzyme METTL3 controls myeloid differentiation of normal hematopoietic and leukemia cells. Nature medicine. 2017 Academic Article GET IT
Times cited: 739
Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma. Science translational medicine. 2017 Academic Article GET IT
Times cited: 39
Functional screen of MSI2 interactors identifies an essential role for SYNCRIP in myeloid leukemia stem cells. Nature genetics. 2017 Academic Article GET IT
Times cited: 63
Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers. Cancer discovery. 2017 Academic Article GET IT
Times cited: 84
Follicular lymphoma: State-of-the-art ICML workshop in Lugano 2015. Hematological oncology. 2017 Review GET IT
Times cited: 10
BCL6 Antagonizes NOTCH2 to Maintain Survival of Human Follicular Lymphoma Cells. Cancer discovery. 2017 Academic Article GET IT
Times cited: 34
Combination Targeted Therapy to Disrupt Aberrant Oncogenic Signaling and Reverse Epigenetic Dysfunction in IDH2- and TET2-Mutant Acute Myeloid Leukemia. Cancer discovery. 2017 Academic Article GET IT
Times cited: 82
Effective Combination Therapies for B-cell Lymphoma Predicted by a Virtual Disease Model. Cancer research. 2017 Academic Article GET IT
Times cited: 11
CD99 is a therapeutic target on disease stem cells in myeloid malignancies. Science translational medicine. 2017 Academic Article GET IT
Times cited: 86
DNA Methylation-Based Biomarkers. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2017 Comment GET IT
Times cited: 6
Aid is a key regulator of myeloid/erythroid differentiation and DNA methylation in hematopoietic stem/progenitor cells. Blood. 2017 Academic Article GET IT
Times cited: 16
Modular Immune Organoids with Integrin Ligand Specificity Differentially Regulate Ex Vivo B Cell Activation. ACS biomaterials science & engineering. 2017 Academic Article GET IT
Times cited: 26
General Biomarker Recommendations for Lymphoma. Journal of the National Cancer Institute. 2016 Academic Article GET IT
Times cited: 1
Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas. Science translational medicine. 2016 Academic Article GET IT
Times cited: 123
The Expanding Role of the BCL6 Oncoprotein as a Cancer Therapeutic Target. Clinical cancer research : an official journal of the American Association for Cancer Research. 2016 Review GET IT
Times cited: 115
DNMT3A mutations promote anthracycline resistance in acute myeloid leukemia via impaired nucleosome remodeling. Nature medicine. 2016 Academic Article GET IT
Times cited: 169
Roles for small noncoding RNAs in silencing of retrotransposons in the mammalian brain. Proceedings of the National Academy of Sciences of the United States of America. 2016 Academic Article GET IT
Times cited: 66
CREBBP Inactivation Promotes the Development of HDAC3-Dependent Lymphomas. Cancer discovery. 2016 Academic Article GET IT
Times cited: 181
The epichaperome is an integrated chaperome network that facilitates tumour survival. Nature. 2016 Academic Article GET IT
Times cited: 167
Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region. Immunity. 2016 Academic Article GET IT
Times cited: 89
EZH2 and BCL6 Cooperate to Assemble CBX8-BCOR Complex to Repress Bivalent Promoters, Mediate Germinal Center Formation and Lymphomagenesis. Cancer cell. 2016 Academic Article GET IT
Times cited: 166
SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents. Cancer research. 2016 Academic Article GET IT
Times cited: 47
Rationally designed BCL6 inhibitors target activated B cell diffuse large B cell lymphoma. The Journal of clinical investigation. 2016 Academic Article GET IT
Times cited: 110
A Highly Sensitive and Robust Method for Genome-wide 5hmC Profiling of Rare Cell Populations. Molecular cell. 2016 Academic Article GET IT
Times cited: 91
Mutant IDH: a targetable driver of leukemic phenotypes linking metabolism, epigenetics and transcriptional regulation. Epigenomics. 2016 Review GET IT
Times cited: 18
The many layers of epigenetic dysfunction in B-cell lymphomas. Current opinion in hematology. 2016 Review GET IT
Times cited: 32
Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. Nature medicine. 2016 Academic Article GET IT
Times cited: 246
A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. JCI insight. 2016 Academic Article GET IT
Times cited: 706
Homeobox NKX2-3 promotes marginal-zone lymphomagenesis by activating B-cell receptor signalling and shaping lymphocyte dynamics. Nature communications. 2016 Academic Article GET IT
Times cited: 36
Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". Nature medicine. 2016 Letter GET IT
Times cited: 7
Genetic and epigenetic heterogeneity in acute myeloid leukemia. Current opinion in genetics & development. 2016 Review GET IT
Times cited: 76
Pathogenic role of B-cell receptor signaling and canonical NF-κB activation in mantle cell lymphoma. Blood. 2016 Academic Article GET IT
Times cited: 107
DNMT3A Haploinsufficiency Transforms FLT3ITD Myeloproliferative Disease into a Rapid, Spontaneous, and Fully Penetrant Acute Myeloid Leukemia. Cancer discovery. 2016 Academic Article GET IT
Times cited: 66
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells. Nature medicine. 2016 Academic Article GET IT
Times cited: 80
Corrigendum: Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2016 Academic Article GET IT
Times cited: 1
miR-181a negatively regulates NF-κB signaling and affects activated B-cell-like diffuse large B-cell lymphoma pathogenesis. Blood. 2016 Academic Article GET IT
Times cited: 41
Selective targeting of BCL6 induces oncogene addiction switching to BCL2 in B-cell lymphoma. Oncotarget. 2016 Academic Article GET IT
Times cited: 25
Dnmt3a regulates myeloproliferation and liver-specific expansion of hematopoietic stem and progenitor cells. Leukemia. 2015 Academic Article GET IT
Times cited: 53
VDJ-Seq: Deep Sequencing Analysis of Rearranged Immunoglobulin Heavy Chain Gene to Reveal Clonal Evolution Patterns of B Cell Lymphoma. Journal of visualized experiments : JoVE. 2015 Academic Article GET IT
Times cited: 13
A Hyperactive Signalosome in Acute Myeloid Leukemia Drives Addiction to a Tumor-Specific Hsp90 Species. Cell reports. 2015 Academic Article GET IT
Times cited: 45
Combinatorial targeting of nuclear export and translation of RNA inhibits aggressive B-cell lymphomas. Blood. 2015 Academic Article GET IT
Times cited: 57
Mechanisms of action of BCL6 during germinal center B cell development. Science China. Life sciences. 2015 Review GET IT
Times cited: 26
Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 34
Transcriptome sequencing reveals thousands of novel long non-coding RNAs in B cell lymphoma. Genome medicine. 2015 Academic Article GET IT
Times cited: 57
Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. The Journal of experimental medicine. 2015 Academic Article GET IT
Times cited: 112
Loss of BAP1 function leads to EZH2-dependent transformation. Nature medicine. 2015 Academic Article GET IT
Times cited: 253
The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development. Nature medicine. 2015 Academic Article GET IT
Times cited: 289
Integrin-specific hydrogels as adaptable tumor organoids for malignant B and T cells. Biomaterials. 2015 Academic Article GET IT
Times cited: 50
DNA Methylation Dynamics of Germinal Center B Cells Are Mediated by AID. Cell reports. 2015 Academic Article GET IT
Times cited: 77
Engineering of a Histone-Recognition Domain in Dnmt3a Alters the Epigenetic Landscape and Phenotypic Features of Mouse ESCs. Molecular cell. 2015 Academic Article GET IT
Times cited: 63
Erk Negative Feedback Control Enables Pre-B Cell Transformation and Represents a Therapeutic Target in Acute Lymphoblastic Leukemia. Cancer cell. 2015 Academic Article GET IT
Times cited: 84
VII. Are lymphomas driven by epigenetic lesions?. Hematological oncology. 2015 Review GET IT
Epigenomic evolution in diffuse large B-cell lymphomas. Nature communications. 2015 Academic Article GET IT
Times cited: 95
Mutational cooperativity linked to combinatorial epigenetic gain of function in acute myeloid leukemia. Cancer cell. 2015 Academic Article GET IT
Times cited: 170
BCL6 orchestrates Tfh cell differentiation via multiple distinct mechanisms. The Journal of experimental medicine. 2015 Academic Article GET IT
Times cited: 176
A roadmap for discovery and translation in lymphoma. Blood. 2015 Letter GET IT
Times cited: 17
Signalling thresholds and negative B-cell selection in acute lymphoblastic leukaemia. Nature. 2015 Academic Article GET IT
Times cited: 102
Identification of FOXM1 as a therapeutic target in B-cell lineage acute lymphoblastic leukaemia. Nature communications. 2015 Academic Article GET IT
Times cited: 39
Self-enforcing feedback activation between BCL6 and pre-B cell receptor signaling defines a distinct subtype of acute lymphoblastic leukemia. Cancer cell. 2015 Academic Article GET IT
Times cited: 92
Enhanced reduced representation bisulfite sequencing for assessment of DNA methylation at base pair resolution. Journal of visualized experiments : JoVE. 2015 Academic Article GET IT
Times cited: 77
Musashi2 sustains the mixed-lineage leukemia-driven stem cell regulatory program. The Journal of clinical investigation. 2015 Academic Article GET IT
Times cited: 76
Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia. 2015 Academic Article GET IT
Times cited: 41
Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. Genome research. 2015 Academic Article GET IT
Times cited: 100
The epigenetic basis of diffuse large B-cell lymphoma. Seminars in hematology. 2015 Review GET IT
Times cited: 40
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. Cell reports. 2014 Academic Article GET IT
Times cited: 206
The H3K27me3 demethylase UTX is a gender-specific tumor suppressor in T-cell acute lymphoblastic leukemia. Blood. 2014 Academic Article GET IT
Times cited: 141
Dynamic evolution of clonal epialleles revealed by methclone. Genome biology. 2014 Academic Article GET IT
Times cited: 50
Microscale Bioadhesive Hydrogel Arrays for Cell Engineering Applications. Cellular and molecular bioengineering. 2014 Academic Article GET IT
Times cited: 106
The BCL6 RD2 domain governs commitment of activated B cells to form germinal centers. Cell reports. 2014 Academic Article GET IT
Times cited: 52
Deep sequencing reveals clonal evolution patterns and mutation events associated with relapse in B-cell lymphomas. Genome biology. 2014 Academic Article GET IT
Times cited: 74
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells. Oncotarget. 2014 Academic Article GET IT
Times cited: 119
Affinity purification probes of potential use to investigate the endogenous Hsp70 interactome in cancer. ACS chemical biology. 2014 Academic Article GET IT
Times cited: 20
Transient expression of Bcl6 is sufficient for oncogenic function and induction of mature B-cell lymphoma. Nature communications. 2014 Academic Article GET IT
Times cited: 72
Hematopoietic stem cell origin of BRAFV600E mutations in hairy cell leukemia. Science translational medicine. 2014 Academic Article GET IT
Times cited: 98
Mechanistic rationale for targeting the unfolded protein response in pre-B acute lymphoblastic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2014 Academic Article GET IT
Times cited: 70
CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. Cell reports. 2014 Academic Article GET IT
Times cited: 130
Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis. Trends in molecular medicine. 2014 Review GET IT
Times cited: 127
High-resolution chromatin immunoprecipitation (ChIP) sequencing reveals novel binding targets and prognostic role for SOX11 in mantle cell lymphoma. Oncogene. 2014 Academic Article GET IT
Times cited: 49
Two splice-factor mutant leukemia subgroups uncovered at the boundaries of MDS and AML using combined gene expression and DNA-methylation profiling. Blood. 2014 Academic Article GET IT
Times cited: 43
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2014 Academic Article GET IT
Times cited: 201
The transcriptional modulator BCL6 as a molecular target for breast cancer therapy. Oncogene. 2014 Academic Article GET IT
Times cited: 55
Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer research. 2014 Academic Article GET IT
Times cited: 184
HSC commitment-associated epigenetic signature is prognostic in acute myeloid leukemia. The Journal of clinical investigation. 2014 Review GET IT
Times cited: 33
Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes. Blood. 2014 Academic Article GET IT
Times cited: 77
PRMT4 blocks myeloid differentiation by assembling a methyl-RUNX1-dependent repressor complex. Cell reports. 2013 Academic Article GET IT
Times cited: 71
Cooperative transcriptional repression by BCL6 and BACH2 in germinal center B-cell differentiation. Blood. 2013 Academic Article GET IT
Times cited: 70
DNMT1-interacting RNAs block gene-specific DNA methylation. Nature. 2013 Academic Article GET IT
Times cited: 384
Structural architecture of the CARMA1/Bcl10/MALT1 signalosome: nucleation-induced filamentous assembly. Molecular cell. 2013 Academic Article GET IT
Times cited: 131
Induction of sarcomas by mutant IDH2. Genes & development. 2013 Academic Article GET IT
Times cited: 123
DNA methylation profiling in human B cells reveals immune regulatory elements and epigenetic plasticity at Alu elements during B-cell activation. Genome research. 2013 Academic Article GET IT
Times cited: 82
Molecular pathways: targeting MALT1 paracaspase activity in lymphoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Review GET IT
Times cited: 25
Mechanism-based epigenetic chemosensitization therapy of diffuse large B-cell lymphoma. Cancer discovery. 2013 Academic Article GET IT
Times cited: 149
Targeting the Hsp90-associated viral oncoproteome in gammaherpesvirus-associated malignancies. Blood. 2013 Academic Article GET IT
Times cited: 59
A hybrid mechanism of action for BCL6 in B cells defined by formation of functionally distinct complexes at enhancers and promoters. Cell reports. 2013 Academic Article GET IT
Times cited: 134
Targeting BCL6 in diffuse large B-cell lymphoma: what does this mean for the future treatment?. Expert review of hematology. 2013 Editorial Article GET IT
Times cited: 18
BACH2 mediates negative selection and p53-dependent tumor suppression at the pre-B cell receptor checkpoint. Nature medicine. 2013 Academic Article GET IT
Times cited: 85
Epigenetics in focus: pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Critical reviews in oncology/hematology. 2013 Review GET IT
Times cited: 23
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies. Leukemia. 2013 Letter GET IT
Times cited: 101
A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature. 2013 Academic Article GET IT
Times cited: 106
LITAF, a BCL6 target gene, regulates autophagy in mature B-cell lymphomas. British journal of haematology. 2013 Academic Article GET IT
Times cited: 37
Integrated genetic and epigenetic analysis of childhood acute lymphoblastic leukemia. The Journal of clinical investigation. 2013 Academic Article GET IT
Times cited: 104
Differentiation therapy for IDH1/2 mutant malignancies. Cell research. 2013 Academic Article GET IT
Times cited: 7
New effector functions and regulatory mechanisms of BCL6 in normal and malignant lymphocytes. Current opinion in immunology. 2013 Review GET IT
Times cited: 53
EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation. Cancer cell. 2013 Academic Article GET IT
Times cited: 608
Discovering what makes STAT signaling TYK in T-ALL. Cancer discovery. 2013 Comment GET IT
Times cited: 3
Imatinib disrupts lymphoma angiogenesis by targeting vascular pericytes. Blood. 2013 Academic Article GET IT
Times cited: 69
Downregulation of FOXP1 is required during germinal center B-cell function. Blood. 2013 Academic Article GET IT
Times cited: 51
An optimized algorithm for detecting and annotating regional differential methylation. BMC bioinformatics. 2013 Academic Article GET IT
Times cited: 88
Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment. Nature immunology. 2013 Academic Article GET IT
Times cited: 77
BCL6 breaks occur at different AID sequence motifs in Ig-BCL6 and non-Ig-BCL6 rearrangements. Blood. 2013 Academic Article GET IT
Times cited: 23
Lineage-specific functions of Bcl-6 in immunity and inflammation are mediated by distinct biochemical mechanisms. Nature immunology. 2013 Academic Article GET IT
Times cited: 90
Notch activation inhibits AML growth and survival: a potential therapeutic approach. The Journal of experimental medicine. 2013 Academic Article GET IT
Times cited: 126
RUNX1 is a key target in t(4;11) leukemias that contributes to gene activation through an AF4-MLL complex interaction. Cell reports. 2013 Academic Article GET IT
Times cited: 108
Differential gene body methylation and reduced expression of cell adhesion and neurotransmitter receptor genes in adverse maternal environment. Translational psychiatry. 2013 Academic Article GET IT
Times cited: 43
Aberration in DNA methylation in B-cell lymphomas has a complex origin and increases with disease severity. PLoS genetics. 2013 Academic Article GET IT
Times cited: 98
Negative regulation of osteoclast precursor differentiation by CD11b and β2 integrin-B-cell lymphoma 6 signaling. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research. 2013 Academic Article GET IT
Times cited: 44
A molecular roadmap of reprogramming somatic cells into iPS cells. Cell. 2012 Academic Article GET IT
Times cited: 632
Cell of origin determines clinically relevant subtypes of MLL-rearranged AML. Leukemia. 2012 Academic Article GET IT
Times cited: 143
Epigenetic repression of miR-31 disrupts androgen receptor homeostasis and contributes to prostate cancer progression. Cancer research. 2012 Academic Article GET IT
Times cited: 150
MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo. Cancer cell. 2012 Academic Article GET IT
Times cited: 187
Targeting lymphomas through MALT1 inhibition. Oncotarget. 2012 Editorial Article GET IT
Times cited: 4
C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia. The Journal of clinical investigation. 2012 Academic Article GET IT
Times cited: 49
SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia. Blood. 2012 Academic Article GET IT
Times cited: 56
Epigenetic therapy leaps ahead with specific targeting of EZH2. Cancer cell. 2012 Academic Article GET IT
Times cited: 1383
Integrative epigenomic analysis identifies biomarkers and therapeutic targets in adult B-acute lymphoblastic leukemia. Cancer discovery. 2012 Academic Article GET IT
Times cited: 74
Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms. Cancer research. 2012 Academic Article GET IT
Times cited: 40
methylKit: a comprehensive R package for the analysis of genome-wide DNA methylation profiles. Genome biology. 2012 Academic Article GET IT
Times cited: 1024
Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis. Nature genetics. 2012 Academic Article GET IT
Times cited: 614
Incidence and clinical implications of ATM aberrations in chronic lymphocytic leukemia. Genes, chromosomes & cancer. 2012 Academic Article GET IT
Times cited: 29
IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics. Nature. 2012 Academic Article GET IT
Times cited: 407
ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer cell. 2012 Academic Article GET IT
Times cited: 455
H2.0-like homeobox regulates early hematopoiesis and promotes acute myeloid leukemia. Cancer cell. 2012 Academic Article GET IT
Times cited: 35
CD25 expression status improves prognostic risk classification in AML independent of established biomarkers: ECOG phase 3 trial, E1900. Blood. 2012 Academic Article GET IT
Times cited: 78
Genome-wide detection of genes targeted by non-Ig somatic hypermutation in lymphoma. PloS one. 2012 Academic Article GET IT
Times cited: 41
Base-pair resolution DNA methylation sequencing reveals profoundly divergent epigenetic landscapes in acute myeloid leukemia. PLoS genetics. 2012 Academic Article GET IT
Times cited: 240
Oncogene-mediated alterations in chromatin conformation. Proceedings of the National Academy of Sciences of the United States of America. 2012 Academic Article GET IT
Times cited: 110
Identification of LMO2 transcriptome and interactome in diffuse large B-cell lymphoma. Blood. 2012 Academic Article GET IT
Times cited: 35
Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood. 2012 Academic Article GET IT
Times cited: 202
The Bcl6-SMRT/NCoR cistrome represses inflammation to attenuate atherosclerosis. Cell metabolism. 2012 Academic Article GET IT
Times cited: 96
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. The New England journal of medicine. 2012 Academic Article GET IT
Times cited: 1497
IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature. 2012 Academic Article GET IT
Times cited: 1461
Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia. Leukemia. 2011 Academic Article GET IT
Times cited: 72
The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell. 2011 Academic Article GET IT
Times cited: 138
SYK inhibition and response prediction in diffuse large B-cell lymphoma. Blood. 2011 Academic Article GET IT
Times cited: 82
Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nature chemical biology. 2011 Academic Article GET IT
Times cited: 213
BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia. The Journal of experimental medicine. 2011 Academic Article GET IT
Times cited: 150
Pre-B cell receptor-mediated activation of BCL6 induces pre-B cell quiescence through transcriptional repression of MYC. Blood. 2011 Academic Article GET IT
Times cited: 48
DNA methyltransferase 1 and DNA methylation patterning contribute to germinal center B-cell differentiation. Blood. 2011 Academic Article GET IT
Times cited: 114
The leukemogenicity of AML1-ETO is dependent on site-specific lysine acetylation. Science (New York, N.Y.). 2011 Academic Article GET IT
Times cited: 170
Epigenetics and B-cell lymphoma. Current opinion in hematology. 2011 Review GET IT
Times cited: 54
Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer cell. 2011 Academic Article GET IT
Times cited: 970
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. Nature. 2011 Academic Article GET IT
Times cited: 161
Aberrant epigenetic and genetic marks are seen in myelodysplastic leukocytes and reveal Dock4 as a candidate pathogenic gene on chromosome 7q. The Journal of biological chemistry. 2011 Academic Article GET IT
Times cited: 39
Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas. PloS one. 2011 Academic Article GET IT
Times cited: 41
Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis. PLoS genetics. 2011 Academic Article GET IT
Times cited: 111
Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell. 2010 Academic Article GET IT
Times cited: 2085
BCL6 repression of EP300 in human diffuse large B cell lymphoma cells provides a basis for rational combinatorial therapy. The Journal of clinical investigation. 2010 Academic Article GET IT
Times cited: 99
Epigenetics in AML. Best practice & research. Clinical haematology. 2010 Review GET IT
Times cited: 27
PHF6 mutations in adult acute myeloid leukemia. Leukemia. 2010 Academic Article GET IT
Times cited: 36
Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1. Blood. 2010 Academic Article GET IT
Times cited: 85
EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis. Blood. 2010 Academic Article GET IT
Times cited: 246
Cell type of origin influences the molecular and functional properties of mouse induced pluripotent stem cells. Nature biotechnology. 2010 Academic Article GET IT
Times cited: 958
DNA methylation signatures define molecular subtypes of diffuse large B-cell lymphoma. Blood. 2010 Academic Article GET IT
Times cited: 121
Genome-wide analysis of DNA binding and transcriptional regulation by the mammalian Doublesex homolog DMRT1 in the juvenile testis. Proceedings of the National Academy of Sciences of the United States of America. 2010 Academic Article GET IT
Times cited: 77
DNMT3B7, a truncated DNMT3B isoform expressed in human tumors, disrupts embryonic development and accelerates lymphomagenesis. Cancer research. 2010 Academic Article GET IT
Times cited: 59
Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies. Clinical lymphoma, myeloma & leukemia. 2010 Academic Article GET IT
Times cited: 45
BCL6 is critical for the development of a diverse primary B cell repertoire. The Journal of experimental medicine. 2010 Academic Article GET IT
Times cited: 95
Genomewide DNA methylation analysis reveals novel targets for drug development in mantle cell lymphoma. Blood. 2010 Academic Article GET IT
Times cited: 122
A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo. Cancer cell. 2010 Academic Article GET IT
Times cited: 241
Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494. Clinical cancer research : an official journal of the American Association for Cancer Research. 2010 Academic Article GET IT
Times cited: 23
NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 2010 Academic Article GET IT
Times cited: 28
Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting. Blood. 2010 Academic Article GET IT
Times cited: 91
DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer cell. 2010 Academic Article GET IT
Times cited: 677
HELP (HpaII tiny fragment enrichment by ligation-mediated PCR) assay for DNA methylation profiling of primary normal and malignant B lymphocytes. Methods in molecular biology (Clifton, N.J.). 2010 Academic Article GET IT
Times cited: 25
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nature medicine. 2009 Academic Article GET IT
Times cited: 141
SAFB1 mediates repression of immune regulators and apoptotic genes in breast cancer cells. The Journal of biological chemistry. 2009 Academic Article GET IT
Times cited: 28
BCL6 modulates tonic BCR signaling in diffuse large B-cell lymphomas by repressing the SYK phosphatase, PTPROt. Blood. 2009 Academic Article GET IT
Times cited: 52
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood. 2009 Academic Article GET IT
Times cited: 293
Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proceedings of the National Academy of Sciences of the United States of America. 2009 Academic Article GET IT
Times cited: 268
High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers. Nucleic acids research. 2009 Academic Article GET IT
Times cited: 131
The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009 Academic Article GET IT
Times cited: 176
Outcome of deferred initial therapy in mantle-cell lymphoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2009 Academic Article GET IT
Times cited: 286
Genome-wide epigenetic analysis delineates a biologically distinct immature acute leukemia with myeloid/T-lymphoid features. Blood. 2009 Academic Article GET IT
Times cited: 78
Genome-wide determination of DNA methylation by Hpa II tiny fragment enrichment by ligation-mediated PCR (HELP) for the study of acute leukemias. Methods in molecular biology (Clifton, N.J.). 2009 Academic Article GET IT
Times cited: 31
Inhibition of DNA methyltransferase activates tumor necrosis factor alpha-induced monocytic differentiation in acute myeloid leukemia cells. Cancer research. 2009 Academic Article GET IT
Times cited: 24
A peptomimetic inhibitor of BCL6 with potent antilymphoma effects in vitro and in vivo. Blood. 2008 Academic Article GET IT
Times cited: 145
Kaiso contributes to DNA methylation-dependent silencing of tumor suppressor genes in colon cancer cell lines. Cancer research. 2008 Academic Article GET IT
Times cited: 88
Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration. PloS one. 2008 Academic Article GET IT
Times cited: 22
HDAC4 promotes growth of colon cancer cells via repression of p21. Molecular biology of the cell. 2008 Academic Article GET IT
Times cited: 172
B-cell lymphoma 6 and the molecular pathogenesis of diffuse large B-cell lymphoma. Current opinion in hematology. 2008 Review GET IT
Times cited: 65
Derepression in the desert: the third workshop on clinical translation of epigenetics in cancer therapeutics. Cancer research. 2008 Conference Paper GET IT
Times cited: 7
BCL6-mediated attenuation of DNA damage sensing triggers growth arrest and senescence through a p53-dependent pathway in a cell context-dependent manner. The Journal of biological chemistry. 2008 Academic Article GET IT
Times cited: 35
Reversible disruption of BCL6 repression complexes by CD40 signaling in normal and malignant B cells. Blood. 2008 Academic Article GET IT
Times cited: 33
Sequential transcription factor targeting for diffuse large B-cell lymphomas. Cancer research. 2008 Academic Article GET IT
Times cited: 27
Therapeutic targeting of the BCL6 oncogene for diffuse large B-cell lymphomas. Leukemia & lymphoma. 2008 Review GET IT
Times cited: 39
An integrative genomic and epigenomic approach for the study of transcriptional regulation. PloS one. 2008 Academic Article GET IT
Times cited: 77
BCL6 represses CHEK1 and suppresses DNA damage pathways in normal and malignant B-cells. Blood cells, molecules & diseases. 2008 Academic Article GET IT
Times cited: 82
Structure of a BCOR corepressor peptide in complex with the BCL6 BTB domain dimer. Molecular cell. 2008 Academic Article GET IT
Times cited: 124
CtBP is an essential corepressor for BCL6 autoregulation. Molecular and cellular biology. 2008 Academic Article GET IT
Times cited: 49
Transitioning from fellowship to a physician-scientist career track. Hematology. American Society of Hematology. Education Program. 2008 Academic Article GET IT
Times cited: 6
CG dinucleotide clustering is a species-specific property of the genome. Nucleic acids research. 2007 Academic Article GET IT
Times cited: 70
Targeting aggressive B-cell lymphomas with cell-penetrating peptides. Biochemical Society transactions. 2007 Review GET IT
Times cited: 9
Bcl-6 mediates the germinal center B cell phenotype and lymphomagenesis through transcriptional repression of the DNA-damage sensor ATR. Nature immunology. 2007 Academic Article GET IT
Times cited: 214
BCL6 programs lymphoma cells for survival and differentiation through distinct biochemical mechanisms. Blood. 2007 Academic Article GET IT
Times cited: 118
Transcriptional signature with differential expression of BCL6 target genes accurately identifies BCL6-dependent diffuse large B cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 2007 Academic Article GET IT
Times cited: 114
Targeting APL fusion proteins by peptide interference. Current topics in microbiology and immunology. 2007 Review GET IT
Times cited: 2
Comparative isoschizomer profiling of cytosine methylation: the HELP assay. Genome research. 2006 Academic Article GET IT
Times cited: 341
Kaiso-deficient mice show resistance to intestinal cancer. Molecular and cellular biology. 2006 Academic Article GET IT
Times cited: 140
Specific peptides for the therapeutic targeting of oncogenes. Current opinion in genetics & development. 2005 Review GET IT
Times cited: 27
Predicting the effect of transcription therapy in hematologic malignancies. Leukemia. 2005 Review GET IT
Times cited: 15
The theoretical basis of transcriptional therapy of cancer: can it be put into practice?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Review GET IT
Times cited: 30
Reprogramming specific gene expression pathways in B-cell lymphomas. Cell cycle (Georgetown, Tex.). 2005 Academic Article GET IT
Times cited: 7
Specific peptide interference reveals BCL6 transcriptional and oncogenic mechanisms in B-cell lymphoma cells. Nature medicine. 2004 Academic Article GET IT
Times cited: 247
The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT. Blood. 2004 Academic Article GET IT
Times cited: 31
Mechanism of SMRT corepressor recruitment by the BCL6 BTB domain. Molecular cell. 2003 Academic Article GET IT
Times cited: 223
ETO protein of t(8;21) AML is a corepressor for Bcl-6 B-cell lymphoma oncoprotein. Blood. 2003 Academic Article GET IT
Times cited: 62
Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best practice & research. Clinical haematology. 2003 Review GET IT
Times cited: 42
Spotlight on acute promyelocytic leukemia: controversies and challenges. Leukemia. 2002 Comment GET IT
Times cited: 1
Histone deacetylases as therapeutic targets in hematologic malignancies. Current opinion in hematology. 2002 Review GET IT
Times cited: 114
Autosomal dominant chorea-acanthocytosis with polyglutamine-containing neuronal inclusions. 2002 GET IT
Times cited: 59
Critical residues within the BTB domain of PLZF and Bcl-6 modulate interaction with corepressors. Molecular and cellular biology. 2002 Academic Article GET IT
Times cited: 174
Translocations of the RARalpha gene in acute promyelocytic leukemia. Oncogene. 2001 Review GET IT
Times cited: 189
AML-1/ETO fusion protein is a dominant negative inhibitor of transcriptional repression by the promyelocytic leukemia zinc finger protein. Blood. 2000 Academic Article GET IT
Times cited: 51
In-depth mutational analysis of the promyelocytic leukemia zinc finger BTB/POZ domain reveals motifs and residues required for biological and transcriptional functions. Molecular and cellular biology. 2000 Academic Article GET IT
Times cited: 154
The ETO protein disrupted in t(8;21)-associated acute myeloid leukemia is a corepressor for the promyelocytic leukemia zinc finger protein. Molecular and cellular biology. 2000 Academic Article GET IT
Times cited: 125
A novel BTB/POZ transcriptional repressor protein interacts with the Fanconi anemia group C protein and PLZF. Blood. 1999 Academic Article GET IT
Times cited: 109
The promyelocytic leukemia zinc finger (PLZF) protein binds DNA in a high molecular weight complex associated with cdc2 kinase. Nucleic acids research. 1999 Academic Article GET IT
Times cited: 55
Identification of novel chromosomal rearrangements in acute myelogenous leukemia involving loci on chromosome 2p23, 15q22 and 17q21. 1999 GET IT
Times cited: 18
Deconstructing a disease: RARalpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood. 1999 Review GET IT
Times cited: 943
The promyelocytic leukemia zinc finger protein affects myeloid cell growth, differentiation, and apoptosis. Molecular and cellular biology. 1998 Academic Article GET IT
Times cited: 148
Reduced and altered DNA-binding and transcriptional properties of the PLZF-retinoic acid receptor-alpha chimera generated in t(11;17)-associated acute promyelocytic leukemia. Oncogene. 1996 Academic Article GET IT
Times cited: 88

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Therapeutic Targeting of SIRT3 for Aggressive and Refractory Lymphomas awarded by National Cancer Institute Principal Investigator 2023 - 2028
Targeting Unmet Needs For B-cell Lymphomas awarded by Leukemia & Lymphoma Society, Inc. Principal Investigator 2022 - 2027
The Role of SPEN as Tumor Suppressor in BN2 DLBCL awarded by Leukemia & Lymphoma Society, Inc. Principal Investigator 2022 - 2025
Targeting Epigenetic Circuits in B-Cell Lymphomas awarded by National Cancer Institute Principal Investigator 2018 - 2025
Precision translation of therapeutic regimens for follicular lymphoma awarded by Institute for Follicular Lymphoma Innovation, Inc. Principal Investigator 2022 - 2024
SETD2 and H1 Project awarded by Epizyme Principal Investigator 2021 - 2024
BioPharma Alliance Agreement- Janssen Research & Development awarded by Janssen Research & Development, LLC Principal Investigator 2021 - 2024
Characterizing The Biological And Mechanistic Nature Of The Elusive Lymphoma Stem Cell awarded by Tri-Institutional Stem Cell Initiative (Weill Cornell) Principal Investigator 2021 - 2023

Characterizing stem cell-like B cell subpopulations and dissecting their role in tumorigenesis awarded by National Cancer Institute Co-Investigator 2023 - 2028
BAF complex deregulation in lymphoma awarded by National Cancer Institute Co-Investigator 2022 - 2027
Role of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapies awarded by National Cancer Institute Co-Investigator 2020 - 2025
Mechanisms of dynamic chromatin reorganization regulating B-cell differentiation and Lymphomagenesis awarded by Starr Cancer Consortium Co-Investigator 2023 - 2024
Role of the stromal microenvironment in B-cell lymphoma progression and immune escape awarded by National Cancer Institute Co-Investigator 2019 - 2024
Role of novel onco-histone mutations in B-cell malignancies awarded by National Cancer Institute Co-Investigator 2019 - 2024

Preventing follicular lymphoma progression and transformation through precision therapy awarded by National Cancer Institute Key Personnel 2022 - 2027
The Impact of Spaceflight and Radiation on Clonal Hematopoiesis awarded by National Aeronautics & Space Administration Key Personnel 2023 - 2026
Epigenetic basis and therapeutic interdiction of FL progression awarded by Lymphoma Research Foundation Key Personnel 2023 - 2026
Exploring the roles of EZH2 mutation for the development of double hit lymphoma and acquisition of chemotherapy resistance awarded by Leukemia & Lymphoma Society, Inc. Key Personnel 2023 - 2025
Precision epigenetic therapy for SETD2+/- B cell lymphomas awarded by Lymphoma Research Foundation Key Personnel 2023 - 2025
Lymph node-targeted multistage chemoimmunotherapy for lymphoma awarded by National Cancer Institute Key Personnel 2020 - 2025
Utilizing EZH2 Inhibition to Improve Immune Therapies in Follicular Lymphoma awarded by Follicular Lymphoma Foundation Key Personnel 2022 - 2024
Role of Chromatin Remodeling Complex BAF in Immunity and Lymphoma awarded by National Cancer Institute Key Personnel 2022 - 2024
Preventing follicular lymphoma progression and transformation through precision therapy awarded by Leukemia & Lymphoma Society, Inc. Key Personnel 2021 - 2024
Role of chromatin remodeling complex BAF in immunity and lymphoma awarded by National Cancer Institute Key Personnel 2020 - 2024
Cohesin complex regulatory proteins and chromosomal architecture in normal and malignant B-cells awarded by American Society of Hematology Inc Key Personnel 2022 - 2023
Targeting immune escape in Cluster 5 DLBCL awarded by AstraZeneca Pharmaceuticals LP Key Personnel 2021 - 2023
Understanding the role of SPEN in DLBCL awarded by Lymphoma Research Foundation Key Personnel 2021 - 2023
Disruption of epigenetic regulation of enhancers in the germinal center reaction drives clonal evolution in Follicular Lymphoma awarded by National Cancer Institute Key Personnel 2020 - 2023
Weill Cornell Medicine (WCM) SPORE in Prostate Cancer awarded by National Cancer Institute Key Personnel 2017 - 2023
Molecular and Translational Oncology Research awarded by National Cancer Institute Key Personnel 2017 - 2023

Lymphoid Experimental Therapeutics Platform to Study Cooperative Signaling in Human Lymphomas awarded by National Institute of General Medical Sciences Principal Investigator Subaward 2020 - 2025
Core: Targeting Enhancer Dysfunction in Hematological Malignancy- Core B awarded by Centers for Disease Control & Prevention Principal Investigator Subaward 2019 - 2024
Targeting Enhancer Dysfunction in Hematological Malignancy- Project 5 awarded by Centers for Disease Control & Prevention Principal Investigator Subaward 2019 - 2024
The impact of changes in chromatin architecture on cancer phenotypes and tumor progression awarded by National Cancer Institute Principal Investigator Subaward 2019 - 2024

more ...

less ...

Background

education and training

M.D., University of Buenos Aires Faculty of Medicine (Argentina) 1990

Contact

full name

Ari M. Melnick

primary email

amm2014@med.cornell.edu

VIVO Weill Cornell Medical College

Ari M. Melnick Professor of Medicine

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email